Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
149.23
-6.46 (-4.15%)
At close: Jun 5, 2026, 4:00 PM EDT
149.00
-0.23 (-0.15%)
After-hours: Jun 5, 2026, 7:58 PM EDT
Revolution Medicines Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
883
Market Cap
31.73B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 11.58M | -23.80M | -67.27% |
| Dec 31, 2022 | 35.38M | 5.99M | 20.38% |
| Dec 31, 2021 | 29.39M | -13.59M | -31.62% |
| Dec 31, 2020 | 42.98M | -7.06M | -14.10% |
| Dec 31, 2019 | 50.04M | 29.88M | 148.16% |
| Dec 31, 2018 | 20.17M | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Regeneron Pharmaceuticals | 14.92B |
| BeOne Medicines AG | 5.70B |
| Incyte | 5.36B |
| argenx SE | 4.74B |
| Alnylam Pharmaceuticals | 4.29B |
| Genmab | 3.90B |
| BioNTech SE | 3.23B |
| Royalty Pharma | 2.44B |
RVMD News
- 5 days ago - Revolution Medicines price target raised to $182 from $165 at RBC Capital - TheFly
- 6 days ago - Wedbush reiterates Outperform on Revolution Medicines after ASCO data - TheFly
- 6 days ago - Revolution Medicines price target raised to $195 from $169 at H.C. Wainwright - TheFly
- 6 days ago - Revolution Medicines price target raised to $195 from $165 at Oppenheimer - TheFly
- 6 days ago - Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's - Reuters
- 6 days ago - Revolution Medicines Transcript: Status update - Transcripts
- 6 days ago - Revolution Medicines Slides: Status update - Filings
- 6 days ago - Revolution Medicines announces results from Phase 3 RASolute 302 trial - TheFly